Effect Of MiR-200a-3p On PDL1 Expression,proliferation And Migration Of Pancreatic Cancer

Objective: Mir-200a-3p can regulate the expression of PD-L1 in lung cancer and breast cancer,but its role in pancreatic cancer has not been reported.This study intends to explore the regulatory effect of miR-200a-3p on the expression of PD-L1 in pancreatic cancer and the proliferation and migration of pancreatic cancer cells,which providing new directions and basis for immunotherapy and basic research of pancreatic cancer.Methods: The data was queried in the TCGA database and the correlation analysis of the co-expression relationship between PD-L1 and miR-200a-3p was performed,and it was found that the expression of miR-200a-3p and PD-L1 gene was negatively correlated.Transfection of PANC-1 and SW1990 cell lines with NC mimics and miR-200a-3p mimics,RT-PCR and Western-Blot methods were used to detect PD-L1 expression,and CCK8 was used to detect cell proliferation.The scratch test detects changes in cell migration..Results: It can be found in the TCGA database that the expression of miR-200a-3p is negatively correlated with the expression of PD-L1.In addition,in the miR-200a-3p mimics group,the expression of PD-L1 m RNA and its protein molecules are significantly lower than the NC mimics group and the blank group.What’s more,compared with the NC group,the cell viability measurement of CCK8 showed that the cell proliferation in the miR-200a-3p mimics group was significantly reduced,while the observation of cell scratches and healing showed that its cell migration ability was significantly reduced.Conclusion: Based on the above studies,miR-200a-3p can reduce the expression of PD-L1 in pancreatic cancer,suggesting that miR-200a-3p may participate in the regulation of PD-L1,thereby inhibiting its expression in cells.In addition,cell scratches and CCK8 cell viability measurements indicate that miR-200a-3p can also inhibit the proliferation and migration of pancreatic cancer cells.Therefore,miR-200a-3p is expected to be a new target for pancreatic cancer targeted therapy,and combined with immunotherapy related to PD-L1 can reduce the resistance of pancreatic cancer therapy to immunotherapy and enhance the clinical treatment effect.